CN102741282A - 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 - Google Patents
针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 Download PDFInfo
- Publication number
- CN102741282A CN102741282A CN2010800622654A CN201080062265A CN102741282A CN 102741282 A CN102741282 A CN 102741282A CN 2010800622654 A CN2010800622654 A CN 2010800622654A CN 201080062265 A CN201080062265 A CN 201080062265A CN 102741282 A CN102741282 A CN 102741282A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- antibody
- tfr
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (21)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR09/06090 | 2009-12-16 | ||
FR0906090A FR2953841B1 (fr) | 2009-12-16 | 2009-12-16 | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
PCT/IB2010/055882 WO2011073943A1 (fr) | 2009-12-16 | 2010-12-16 | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102741282A true CN102741282A (zh) | 2012-10-17 |
CN102741282B CN102741282B (zh) | 2015-03-25 |
Family
ID=42668668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080062265.4A Expired - Fee Related CN102741282B (zh) | 2009-12-16 | 2010-12-16 | 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130045206A1 (zh) |
EP (1) | EP2513143B1 (zh) |
JP (1) | JP2013527129A (zh) |
CN (1) | CN102741282B (zh) |
BR (1) | BR112012014984A2 (zh) |
CA (1) | CA2784404A1 (zh) |
FR (1) | FR2953841B1 (zh) |
WO (1) | WO2011073943A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104231080A (zh) * | 2013-03-15 | 2014-12-24 | 中国医学科学院药物研究所 | 全人源抗人白介素17a单链抗体 |
US9593165B2 (en) | 2012-11-08 | 2017-03-14 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
CN111057151A (zh) * | 2014-01-06 | 2020-04-24 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
CN113999312A (zh) * | 2015-06-24 | 2022-02-01 | 豪夫迈·罗氏有限公司 | 具有定制亲和力的抗转铁蛋白受体抗体 |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA034333B1 (ru) | 2010-11-30 | 2020-01-29 | Дженентек, Инк. | Варианты антитела для переноса соединения через гематоэнцефалический барьер |
JP5939855B2 (ja) * | 2012-03-23 | 2016-06-22 | 国立大学法人 宮崎大学 | トランスフェリン受容体抗体 |
CN103254280A (zh) * | 2013-03-07 | 2013-08-21 | 广州暨南大学医药生物技术研究开发中心 | 具有肿瘤细胞靶向结合能力的短肽及其应用 |
WO2014144060A1 (en) * | 2013-03-15 | 2014-09-18 | Alper Biotech, Llc | Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof |
EP4029880A1 (en) * | 2015-05-04 | 2022-07-20 | CytomX Therapeutics, Inc. | Activatable anti-cd71 antibodies, and methods of use thereof |
RU2737637C2 (ru) * | 2015-07-22 | 2020-12-01 | Инатерис | Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
LT3455261T (lt) | 2016-05-13 | 2022-11-10 | Bioatla, Inc. | Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas |
JP2018024615A (ja) * | 2016-08-10 | 2018-02-15 | 学校法人 聖マリアンナ医科大学 | Htlv−1関連炎症性疾患を治療する医薬組成物 |
FR3062213B1 (fr) * | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
KR20190134654A (ko) | 2017-03-09 | 2019-12-04 | 싸이톰스 테라퓨틱스, 인크. | Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법 |
EP3762420A1 (en) | 2018-03-09 | 2021-01-13 | CytomX Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
EP3883964A1 (en) * | 2018-11-20 | 2021-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen |
WO2020104479A1 (en) * | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
JP2022548310A (ja) | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法 |
EP4370539A1 (en) * | 2021-07-16 | 2024-05-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric tfr1 |
US11827702B2 (en) | 2021-09-01 | 2023-11-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0882794A2 (en) * | 1997-03-19 | 1998-12-09 | Kyowa Hakko Kogyo Co., Ltd. | Human complementarity determining region (CDR)-grafted antibody to ganglioside gm2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9225453D0 (en) * | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US7112661B1 (en) * | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
US9034329B2 (en) * | 1999-02-22 | 2015-05-19 | Georgetown University | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
-
2009
- 2009-12-16 FR FR0906090A patent/FR2953841B1/fr not_active Expired - Fee Related
-
2010
- 2010-12-16 US US13/515,551 patent/US20130045206A1/en not_active Abandoned
- 2010-12-16 JP JP2012543982A patent/JP2013527129A/ja active Pending
- 2010-12-16 WO PCT/IB2010/055882 patent/WO2011073943A1/fr active Application Filing
- 2010-12-16 CN CN201080062265.4A patent/CN102741282B/zh not_active Expired - Fee Related
- 2010-12-16 EP EP10812912.3A patent/EP2513143B1/fr not_active Not-in-force
- 2010-12-16 CA CA2784404A patent/CA2784404A1/fr not_active Abandoned
- 2010-12-16 BR BR112012014984A patent/BR112012014984A2/pt not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0882794A2 (en) * | 1997-03-19 | 1998-12-09 | Kyowa Hakko Kogyo Co., Ltd. | Human complementarity determining region (CDR)-grafted antibody to ganglioside gm2 |
Non-Patent Citations (1)
Title |
---|
MARIE-ALIX POUL等: "Selection of Tumor-Specific Internalizing Human Antibodies from Phage Libraries", 《J.MOL.BIOL》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9593165B2 (en) | 2012-11-08 | 2017-03-14 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
CN104231080A (zh) * | 2013-03-15 | 2014-12-24 | 中国医学科学院药物研究所 | 全人源抗人白介素17a单链抗体 |
CN104231080B (zh) * | 2013-03-15 | 2019-07-02 | 中国医学科学院药物研究所 | 全人源抗人白介素17a单链抗体 |
CN111057151A (zh) * | 2014-01-06 | 2020-04-24 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
CN111057151B (zh) * | 2014-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
CN113999312A (zh) * | 2015-06-24 | 2022-02-01 | 豪夫迈·罗氏有限公司 | 具有定制亲和力的抗转铁蛋白受体抗体 |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
FR2953841B1 (fr) | 2011-12-30 |
EP2513143A1 (fr) | 2012-10-24 |
US20130045206A1 (en) | 2013-02-21 |
WO2011073943A1 (fr) | 2011-06-23 |
BR112012014984A2 (pt) | 2017-01-31 |
EP2513143B1 (fr) | 2016-10-12 |
CA2784404A1 (fr) | 2011-06-23 |
FR2953841A1 (fr) | 2011-06-17 |
JP2013527129A (ja) | 2013-06-27 |
CN102741282B (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102741282A (zh) | 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 | |
US11802158B2 (en) | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same | |
US20220073640A1 (en) | Cd133-binding agents and uses thereof | |
CN109071654B (zh) | 靶向Fc受体样5的抗体及使用方法 | |
CN102421802B (zh) | 人源化的axl抗体 | |
TWI564306B (zh) | 雙特異性抗體 | |
AU2011223547B2 (en) | Monoclonal antibodies directed to CD52 | |
JP2020513786A (ja) | Cd47抗原結合単位およびその使用 | |
JP2023098966A (ja) | 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
WO2002072635A2 (en) | Specific binding members | |
CN103168104A (zh) | 抗肿瘤抗原抗体及其使用方法 | |
JP2021530251A (ja) | 新規な抗体ならびにそれを調製および使用するための方法 | |
CN105164160A (zh) | 特异性结合her2的抗体 | |
JP2016179978A (ja) | Cd20に対するモノクローナル抗体 | |
US11643437B2 (en) | Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics | |
CN107148282A (zh) | 结合cxcr3的抗原结合蛋白 | |
AU2017306506A1 (en) | Antibody to programmed cell death 1 (PD-1) and use thereof | |
US20220041749A1 (en) | Antibodies specific to muc18 | |
CN115175694A (zh) | 抗baff受体抗体及其用途 | |
CA2962157A1 (en) | Cd133-binding agents and uses thereof | |
WO2023190465A1 (ja) | 抗ヒトsema7a抗体 | |
CN107207590A (zh) | 抗cxcl12抗体分子及其用途 | |
MOFFAT et al. | Patent 2962157 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BOARD OF UNIVERSITY OF CALIFORNIA ECOLE NORMALE SU Free format text: FORMER OWNER: BOARD OF UNIVERSITY OF CALIFORNIA Effective date: 20140702 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140702 Address after: France Applicant after: National Research Center Applicant after: The Regents of the University of California Applicant after: ECOLE NORMALE SUPERIEURE DE CACHAN Applicant after: Couvreur Patrick Address before: France Applicant before: National Research Center Applicant before: The Regents of the University of California |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150325 Termination date: 20151216 |
|
EXPY | Termination of patent right or utility model |